Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06838676 · ClinicalTrials.gov registry record · Phase 2
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
A Phase 2 study of Diffuse Intrinsic Pontine Gliomas (DIPG) and Progressive DIPG, sponsored by Nationwide Children's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT06838676: Recruiting Phase 2 study of Diffuse Intrinsic Pontine Gliomas (DIPG) and Progressive DIPG, sponsored by Nationwide Children's Hospital.
NCT06838676 is a Phase 2 study of Diffuse Intrinsic Pontine Gliomas (DIPG) and Progressive DIPG that is actively recruiting participants, run by Nationwide Children's Hospital. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 19 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06838676, a Phase 2 study of Diffuse Intrinsic Pontine Gliomas (DIPG) and Progressive DIPG, is actively recruiting participants, sponsored by Nationwide Children's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
Primary Outcome
To assess the overall survival for newly-diagnosed patients with DIPG treated with RT followed by ACT001.
Conditions Studied
Interventions
- DRUG ACT001
Study Locations (20)
Ohio
- Cincinnati Children's Hospital - Cincinnati
- Nationwide Children's Hospital - Columbus
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- Nicklaus Children's Hospital - Miami
Georgia
- Emory University/Children's Healthcare of Atlanta - Atlanta
Michigan
- C.S. Mott Children's Hospital - Ann Arbor
Missouri
- St. Louis Children's Hospital - St Louis
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-07-10 |
| Est. Completion | 2035-07 |
| Phase | Phase 2 |
What NCT06838676 shows while recruiting
NCT06838676 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 5 conditions, with Diffuse Intrinsic Pontine Gliomas (DIPG) appearing as the primary indexed condition, and to 1 intervention - of which ACT001 is the first listed.
NCT06838676 names 20 study sites across 19 states, led by Ohio, Colorado, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06838676 about?
NCT06838676 is a clinical study titled "ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas". This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
What is the current status of trial NCT06838676?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-07-10. Estimated completion is 2035-07.
What conditions does trial NCT06838676 study?
This clinical trial studies the following conditions: Diffuse Intrinsic Pontine Gliomas (DIPG), Progressive DIPG, Refractory DIPG, Recurrent DIPG, H3K27-altered High Grade Glioma.
What interventions are being tested in trial NCT06838676?
The interventions under investigation include: ACT001 (DRUG).
Who is sponsoring clinical trial NCT06838676?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06838676 being conducted?
This trial has 20 study locations across Colorado, District of Columbia, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Intrinsic Pontine Gliomas (DIPG)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06838676's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI